VERAXA Biotech (NASDAQ: VRXA) announced today that its bispecific antibody-drug conjugate (bsADC) program, VXA-222, has reached a key technical milestone under its collaboration with OmniAb. OmniAb successfully completed its discovery work, allowing the program to advance into its next development phase. VXA-222 is designed to target two tumor antigens simultaneously using an “AND-gate” approach, which aims to improve precision in treating solid tumors by ensuring the drug activates only in the presence of both targets.
The collaboration, launched in May 2025, leverages OmniAb’s antibody discovery technologies, including its OmniClic platform, while VERAXA applies its proprietary linker technology and conjugation expertise to develop and validate the lead bsADC candidate. Under the terms, VERAXA holds exclusive rights to develop and commercialize products arising from the collaboration, with OmniAb entitled to a share of specified revenue from resulting products. The full press release is available at https://ibn.fm/qMRuJ.
VERAXA Biotech is focused on building a pipeline of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company’s BiTAC platform and quality-by-design principles guide its rapid advancement of ADCs and proprietary formats into clinical development. Founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), VERAXA aims to transform cancer treatment by enhancing specificity and reducing off-target effects. More information about VRXA can be found at https://ibn.fm/VRXA.
The advancement of VXA-222 represents a significant step in the development of more precise cancer therapies. The AND-gate approach could potentially reduce toxicity and improve efficacy compared to traditional ADCs that target a single antigen. This milestone also validates the collaborative model between VERAXA and OmniAb, combining discovery platforms with proprietary conjugation technology. As the program moves forward, VERAXA will focus on preclinical development and eventually clinical trials, with the goal of addressing unmet needs in solid tumor treatment.
Forward-looking statements in this announcement involve risks and uncertainties that may cause actual results to differ materially. These include factors discussed in the company’s filings with the SEC. The company undertakes no obligation to update forward-looking statements except as required by law.
